Skip to main content
Premium Trial:

Request an Annual Quote

Seegene, Shimadzu Ink Molecular Dx Pact

NEW YORK (GenomeWeb News) – Seegene and Shimadzu jointly announced today that they will collaborate on developing molecular diagnostics tests that will run on Shimadzu’s MultiNA high-speed electrophoresis system.
 
Seegene makes the Seeplex family of PCR-based, multi-pathogen tests. The Rockville, Md.-based firm makes screening tests for STDs, respiratory viruses, human papillomavirus, sepsis, and pneumonia, it said.
 
Shimadzu’s MultiNA platform, which is indicated for research use only, uses microchip technology to perform fully automated, high-speed electrophoresis separation, fluorescence detection, and high-sensitivity analysis.
 
Jong-Yoon Chun, founder and CEO of Seegene, said that Shimadzu’s MultiNA platform is “a perfect match for the Seeplex family of multi-pathogen tests.”
 
 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more